Product nameAnti-VEGF Receptor 2 (phospho Y951) antibody
See all VEGF Receptor 2 primary antibodies
DescriptionRabbit polyclonal to VEGF Receptor 2 (phospho Y951)
SpecificityThis antibody is specific for VEGF Receptor 2 only when phosphorylated at tyrosine 951.
Tested applicationsSuitable for: WB, ELISA, IHC-P, ICC/IFmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat
Synthetic phosphopeptide derived from Human VEGF Receptor 2 around the phosphorylation site of tyrosine 951.
- Breast carcinoma tissue and SK-OV3 cell extract.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Concentration information loading...
PurityImmunogen affinity purified
Purification notesThe antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Our Abpromise guarantee covers the use of ab38473 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 151 kDa).|
|IHC-P||Use at an assay dependent concentration.|
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- CD309 antibody
- CD309 antigen antibody
- EC 126.96.36.199 antibody
ab38473 at a 1:50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using Immunohistochemistry, Paraffin Embedded Tissue.
Left image : untreated.
Right image : treated with phosphopeptide.
All lanes : Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473) at 1/500 dilution
Lane 1 : SK-OV3 cell extract (5-30ug of total protein).
Lane 2 : SK-OV3 cell extract (5-30ug of total protein). Treated with phosphopeptide.
All lanes : Alkaline Phosphatase Goat Anti-Rabbit IgG (H+L)
Predicted band size: 151 kDa
Observed band size: 190 kDa why is the actual band size different from the predicted?
This product has been referenced in:
- Li C et al. HIF-1a/VEGF signaling-mediated epithelial-mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells. Phytother Res 33:798-807 (2019). Read more (PubMed: 30653763) »
- Huang M et al. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol 18:169 (2018). Read more (PubMed: 30400838) »